drugset / Trial / NCT00451256

Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

NCT00451256 ↗

Phase 2 Terminated 600 enrolled Sarepta Therapeutics, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

For some people who have heart by-pass surgery, the vein that is used to by-pass a blockage will, after some time, become narrowed and possibly blocked. AVI-5126 blocks a gene that is believed to be responsible for the events in the blood vessel that cause this narrowing. Therefore, exposing the vein to AVI-5126 before it is attached to the coronary artery may result in less problems with these vein grafts later on. This study will determine if this procedure is both safe and effective.

Timeline

Start
2007-03
Primary completion
2007-11
Completion
2009-03

Outcome

Outcome not reported

Stopped: “Protocol-defined outcome in terms of efficacy would not be achieved.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AVI-5126 Antisense oligonucleotide — Other